Clinical Trial Update: Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tolerability and effects of ALK-001 in Stargardt disease. The study is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stargardt Disease

Drugs mentioned

• ALK-001

Snippet

Sponsor: Alkeus Pharmaceuticals, Inc. | Conditions: Stargardt Disease, Stargardt Macular Degeneration | Phase 2 | Status: ENROLLING_BY_INVITATION